| Date | Title | Description |
| 14.07.2026 | Avendus Future Leaders Fund III invests Rs 140 Cr in PPFAS, eyes Rs 1,800 Cr final close | Avendus Future Leaders Fund III (FLF), the private strategies fund of the Avendus Group, has invested approximately Rs 140 crore in Parag Parikh Financial Advisory Services (PPFAS). The fund also announced that it is on track to achieve its... |
| 14.07.2026 | Avendus Future Leaders Fund III invests Rs 140 crore in PPFAS | Avendus Future Leaders Fund III has invested around Rs 140 crore in Parag Parikh Financial Advisory Services (PPFAS) through a secondary transaction.
Advertisment
The fund acquired about a 1% stake by purchasing shares from PPFAS chairman a... |
| 14.07.2026 | Avendus PE fund invests in Parag Parikh Financial ahead of final close | Ritesh Chandra, managing director, Avendus Future Leaders Fund
Mumbai-based financial services company Avendus Capital has invested Rs 140 crore ($14.5 million) in Parag Parikh Financial Advisory Services (PPFAS) from its third private equi... |
| 16.08.2025 | [Weekly funding roundup Aug 9-16] VC inflow into Indian startups on the rise | Indian startups see venture capital (VC) funding steadily rise in August as the startup ecosystem clocks a few large number of deals.
In the second week of August, startups raised a total of $324 million across 27 deals in VC funding compar... |
| 15.08.2025 | Dealmakers' Digest: Hottest Startup Cheques This Week (August 09–14) This week's deals highlight investor appetite for health savings platforms, instant groceries, luxury retail, AI storytelling, and ... | The Indian startup ecosystem witnessed an impressive flow of capital this week, with companies across medtech, quick commerce, life sciences, luxury retail, AI-powered content creation, and on-demand services raising significant funds. From... |
| 14.08.2025 | India's CRDMO Market Attracts Major Investment as Aragen Secures Rs 300 Cr | Avendus Future Leaders Fund III, alongside SBI Life Insurance, recently invested Rs 300 crore in Aragen Life Sciences. This strategic funding highlights robust confidence in India's booming Contract Research, Development, and Manufacturing ... |
| 13.08.2025 | Avendus Fund leads Rs 300 Cr investment in Aragen Life Sciences | Avendus Future Leaders Fund III, the flagship private strategies vehicle of Avendus Group, has led a Rs 300 crore ($36 million) investment in Aragen Life Sciences, one of India’s largest contract research, development, and manufacturing org... |
| 13.08.2025 | Avendus PE leads Aragen funding, looks to close Fund III by year-end | - |
| 13.08.2025 | Avendus PE fund, SBI Life bet on Aragen Life Sciences | Manni Kantipudi, CEO, Aragen Life Sciences
The Avendus Future Leaders Fund, a private equity vehicle managed by Mumbai-based investment bank and asset manager Avendus Group, and SBI Life Insurance have picked up a minority stake in contract... |
| 28.05.2025 | Quadria Capital's Bold Bet on Asian Healthcare: A $1 Billion Investment Surge | In a world where healthcare is a lifeline, Quadria Capital has thrown down the gauntlet. The New Delhi-based private equity firm recently announced the final close of its third healthcare-focused fund, amassing a staggering $1.07 billion. T... |
| 27.05.2025 | Quadria Capital Closes US$1 Billion Fund III to Back Healthcare Companies Across Asia | Quadria Capital, a New Delhi, India-based healthcare-focused private equity firm, announced the final close of its Fund III with US$1.07 Billion in total commitments, exceeding its original $800M target.
The fundraise comprised over US$954M... |
| 27.05.2025 | Quadria Capital closes over a $1B fund | Quadria Capital on Tuesday announced the final close of its third healthcare-focused fund at $1.07 billion, exceeding its original target of $800 million. The oversubscribed fund includes $954 million in primary capital and $114 million in ... |
| 27.05.2025 | Quadria Capital Closes Oversubscribed USD 1 Bn Fund III to Power Asia's Healthcare Future Quadria's Fund III, 40% deployed, backs Aragen, NephroPlus, and Maxivision, aiming to build a 10-company portf... | In a landmark move underscoring global confidence in Asia's healthcare potential, Quadria Capital, a leading healthcare-focused private equity firm, has announced the final close of Fund III with total commitments of USD 1.07 billion, far e... |
| 21.05.2025 | Advances in HPAPI Development and Regulatory Strategy, Upcoming Webinar Hosted by Xtalks | www.aragen.com
In this free webinar, gain insight into the current trends in highly potent active pharmaceutical ingredient (HPAPI) R&D, including formulation and process innovations. Attendees will learn how HPAPIs deliver therapeutic ... |
| 16.04.2025 | Enhancing mAb Platform Process using Membrane Affinity Chromatography for FIH Molecules, Upcoming Webinar Hosted by Xtalks | www.aragen.com
In this free webinar, learn how Protein A membrane chromatography enhances monoclonal antibody (mAb) purification, offering higher throughput and reduced processing times. Attendees will gain insight into how this technology ... |
| 18.01.2025 | Money Matters: This Week's Top Startup Funding Stories (Jan 10–17) The week from January 10 to January 17 witnessed remarkable funding activity in India's startup ecosystem, underscoring the sector's ... |
1. Aragen Life Sciences
Aragen Life Sciences is a Hyderabad-based Contract Research, Development, and Manufacturing Organization (CRDMO) catering to the life sciences industry. Formerly GVK Biosciences, the company offers end-to-end soluti... |
| 14.01.2025 | Quadria Capital's $100 Million Bet on Aragen: A Strategic Move in Pharma Outsourcing | In the ever-evolving landscape of pharmaceuticals, the recent $100 million investment by Quadria Capital in Aragen Life Sciences marks a significant milestone. This deal, announced on January 13, 2025, positions Aragen as a key player in th... |
| 13.01.2025 | Quadria Capital invests $100 million in Aragen to boost pharma outsourcing services | Contract research, development and manufacturing organisation Aragen has secured a $100 million investment from Quadria Capital, an Asia healthcare-focused private equity fund.
This gives Quadria a minority stake in Aragen, at a valuation o... |
| 13.01.2025 | Quadria bets $100 mn on IPO-bound contract drugs manufacturer Aragen | Manni Kantipudi, CEO, Aragen Life Sciences
Healthcare-focused private equity firm Quadria Capital is investing $100 million (about Rs 860 crore) in Hyderabad-based contract drug development and manufacturing company Aragen Life Sciences Ltd... |
| 23.09.2024 | PROTACs: Breaking Boundaries in Drug Discovery, Upcoming Webinar Hosted by Xtalks | www.aragen.com/solutions/small-molecules/discovery/integrated-discovery/
In this free webinar, learn proteolysis targeting chimeras (PROTACs) can transform drug discovery by selectively degrading specific proteins. Attendees will learn how ... |
| 27.07.2024 | GVK Power's Insolvency: A Cautionary Tale for India's Infrastructure Sector | In the world of business, the rise and fall of giants often serve as cautionary tales. GVK Power and Infrastructure, once a beacon of hope in India's infrastructure landscape, now finds itself teetering on the brink of insolvency. This saga... |
| 27.07.2024 | The Future of Brain Health: ViewMind's Revolutionary Approach | In the realm of healthcare, innovation is the lifeblood that keeps the industry vibrant. Enter ViewMind, a company that has recently captured the spotlight by winning the 2024 North American Technology Innovation Leadership Award from Frost... |
| 26.07.2024 | GVK power faces insolvency, but GVK group continues interests
India to reach 300 MT by 2030 in steel production; Deloitte & ISA
300,000 people left jobless in 10 years post-closing of 49,000 MSMEs... | POWER & RENEWABLE ENERGY GVK power faces insolvency, but GVK group continues interests
26 Jul 2024 5 Min Read CW Team
In August 2020, it was announced by GVK Power that it and its subsidiaries involved in airport businesses had reached ... |
| 24.07.2024 | Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services | Aragen Life Sciences Ltd. excels in providing end-to-end drug discovery and development solutions, showcasing its innovative approaches and strong commitment to sustainability and customer satisfaction.
SAN ANTONIO, July 24, 2024 /PRNewswir... |
| 10.07.2024 | Process Development of New Chemical Entities -- Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer, Upcoming Webinar Hosted by Xtalks | www.aragen.com/solutions/small-molecules/discovery/integrated-discovery
In this free webinar, learn about the essential elements of a process development program for new chemical entities. Learn how to develop a robust process in line with ... |
| 27.02.2023 | The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development, Upcoming Webinar Hosted by Xtalks | The webinar will cover current technologies used to assess the qualities of the target biotherapeutics, screening assays for potential biologics and approaches implemented for validating hits.
TORONTO (PRWEB) February 27, 2023
Bioanalytical... |
| 15.09.2022 | Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform, Upcoming Webinar Hosted by Xtalks | Improved process design as well as vector modifications can help address both limitations to improve titers and to achieve faster results for expediting therapeutic objectives.
TORONTO (PRWEB) September 15, 2022
Chinese hamster ovary (CHO) ... |
| 11.08.2022 | Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models, Upcoming Webinar Hosted by Xtalks | Several key modulators in the hostile brain tumor microenvironment promote cancer cell proliferation, apoptosis, metabolism, growth factor signaling, migration and invasion. There is a growing need to understand brain metastases.
TORONTO (P... |
| 15.06.2022 | Development of Covalent Drugs with New Emerging Technologies, Upcoming Webinar Hosted by Xtalks | Covalent therapeutics can also be a strategy to overcome drug-resistance mutations in the gene encoding the target protein like in case of the epidermal growth factor receptor (EGFR).
TORONTO, Ontario (PRWEB) June 15, 2022
Covalent drugs co... |
| 17.03.2022 | Accelerating Biologics Development to Medicines: Key Drivers of Success, Upcoming Webinar Hosted by Xtalks | It is important to evaluate multiple cell line development (CLD) platforms to determine which
TORONTO (PRWEB) March 17, 2022
The biopharmaceutical industry has made great strides in delivering cost-effective therapies to the market in the s... |
| 08.09.2021 | Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions, Upcoming Webinar Hosted by Xtalks | Apart from the knowledge of various formulation parameters, a preclinical formulator should have understanding of impact of physchem properties on drug absoprion, toxicology, pharmacokinetics and analytical techniques.
TORONTO, Ontario (PRW... |
| - | Aragen secures $100M funding from Quadria Capital
Recommended Stories For You | Contract research, development and manufacturing organisation Aragen on Monday said it has secured $100 million investment from private equity fund Quadria Capital.
The investment will result in Quadria acquiring a minority stake in Aragen,... |
